Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	58.44	51.49	43.52	17.4	4.23
Revenue Growth (YoY)	13.49%	18.32%	150.08%	311.71%	112.41%
Cost of Revenue	5.28	4.54	4.41	2.08	2.33
Gross Profit	53.16	46.95	39.12	15.32	1.9
Selling, General & Admin	74.49	72.15	67.07	49.47	46.61
Research & Development	61.06	53.46	50.08	28.69	41.09
Operating Expenses	135.54	125.61	117.15	78.17	87.7
Operating Income	-82.38	-78.65	-78.04	-62.85	-85.8
Interest Expense / Income	11.34	7.02	6.67	6.77	6.1
Other Expense / Income	-12.98	-14.64	-78.16	86.02	-5.53
Pretax Income	-80.74	-71.04	-6.55	-155.64	-86.37
Net Income	-80.74	-71.04	-6.55	-155.64	-86.37
Shares Outstanding (Basic)	80	77	76	61	45
Shares Outstanding (Diluted)	86	83	82	61	45
Shares Change	3.57%	0.59%	35.24%	34.19%	18.78%
EPS (Basic)	-1.01	-0.92	-0.09	-2.56	-1.91
EPS (Diluted)	-1.02	-0.97	-0.98	-2.56	-1.91
Free Cash Flow	-76.32	-63.32	-66.74	-54.4	-79.82
Free Cash Flow Per Share	-0.96	-0.82	-0.87	-0.90	-1.76
Gross Margin	90.96%	91.18%	89.88%	88.03%	45.00%
Operating Margin	-140.96%	-152.74%	-179.30%	-361.13%	-2029.86%
Profit Margin	-138.14%	-137.95%	-15.06%	-894.31%	-2043.34%
Free Cash Flow Margin	-130.59%	-122.96%	-153.36%	-312.56%	-1888.24%
EBITDA	-66.42	-61.91	2.54	-146.1	-77.74
EBITDA Margin	-113.64%	-120.22%	5.83%	-839.48%	-1839.15%
Depreciation & Amortization	2.98	2.11	2.42	2.77	2.53
EBIT	-69.4	-64.02	0.12	-148.87	-80.27
EBIT Margin	-118.74%	-124.32%	0.27%	-855.42%	-1899.01%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).